| Tailoring nanoparticle designs to target cancer based on tumor pathophysiology EA Sykes, Q Dai, CD Sarsons, J Chen, JV Rocheleau, DM Hwang, ... Proceedings of the National Academy of Sciences 113 (9), E1142-E1151, 2016 | 273 | 2016 |
| Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism LM Tsujikawa, L Fu, S Das, C Halliday, BD Rakai, SC Stotz, CD Sarsons, ... Clinical epigenetics 11, 1-21, 2019 | 97 | 2019 |
| Apabetalone downregulates factors and pathways associated with vascular calcification D Gilham, LM Tsujikawa, CD Sarsons, C Halliday, S Wasiak, SC Stotz, ... Atherosclerosis 280, 75-84, 2019 | 53 | 2019 |
| Surface-grafted polyethylene glycol conformation impacts the transport of PEG-functionalized liposomes through a tumour extracellular matrix model HI Labouta, MJ Gomez-Garcia, CD Sarsons, T Nguyen, J Kennard, W Ngo, ... RSC advances 8 (14), 7697-7708, 2018 | 47 | 2018 |
| Quantum dot interactions and flow effects in angiogenic zebrafish (Danio rerio) vessels and human endothelial cells XY Jiang, CD Sarsons, MJ Gomez-Garcia, DT Cramb, KD Rinker, ... Nanomedicine: Nanotechnology, Biology and Medicine 13 (3), 999-1010, 2017 | 25 | 2017 |
| Understanding and improving assays for cytotoxicity of nanoparticles: what really matters? HI Labouta, C Sarsons, J Kennard, MJ Gomez-Garcia, K Villar, H Lee, ... RSC advances 8 (41), 23027-23039, 2018 | 18 | 2018 |
| Pd(η3-1-PhC3H4)(η5-C5H5), an Unusually Effective Catalyst Precursor for Heck–Mizoroki and Sonogashira Cross-Coupling Reactions Catalyzed by Bis … AW Fraser, BE Jaksic, R Batcup, CD Sarsons, M Woolman, MC Baird Organometallics 32 (1), 9-11, 2013 | 14 | 2013 |
| Maltol‐Functionalized Fe3O4 Nanoparticles as T2 Magnetic Resonance Imaging Contrast Agents TW Clements, C Sarsons, CM Platnich, A Banerjee, B Blasiak, B Tomanek, ... ChemistrySelect 1 (8), 1602-1606, 2016 | 13 | 2016 |
| Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators LM Tsujikawa, OA Kharenko, SC Stotz, BD Rakai, CD Sarsons, D Gilham, ... Biomedicine & Pharmacotherapy 152, 113230, 2022 | 9 | 2022 |
| Testing nanoparticles for angiogenesis-related disease: Charting the fastest route to the clinic CD Sarsons, A Tekrony, K Yaehne, S Childs, KD Rinker, D Cramb Journal of Biomedical Nanotechnology 10 (9), 1641-1676, 2014 | 9 | 2014 |
| Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment D Gilham, S Wasiak, BD Rakai, L Fu, LM Tsujikawa, CD Sarsons, ... Biomedicines 11 (6), 1663, 2023 | 4 | 2023 |
| Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells S Wasiak, LM Tsujikawa, E Daze, D Gilham, SC Stotz, BD Rakai, ... Atherosclerosis 364, 10-19, 2023 | 3 | 2023 |
| Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation L Fu, D Gilham, SC Stotz, CD Sarsons, BD Rakai, LM Tsujikawa, ... International Immunopharmacology 117, 109929, 2023 | 2 | 2023 |
| Apabetalone (RVX-208) inhibits key pro-atherogenic mediators and pathways in diabetes and inflammatory conditions; in vitro and in patients LM Tsujikawa, B Rakai, S Das, C Halliday, L Fu, D Gilham, C Sarsons, ... Arterioscler. Thromb. Vasc. Biol 39, A407-A407, 2019 | 2 | 2019 |
| Apabetalone (RVX-208) Suppresses Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and LPS-Challenged Mouse Liver and Monocyte Adhesiveness to … L Tsujikawa, E Daze, L Fu, S Wasiak, CD Sarsons, C Halliday, SC Stotz, ... Circulation 138, 2018 | 2 | 2018 |
| Apabetalone (RVX-208) reduces ACE2 expression in human cell culture systems, which could attenuate SARS-CoV-2 viral entry D Gilham, L Fu, LM Tsujikawa, B Rakai, S Wasiak, S Stotz, C Sarsons, ... Circulation 142 (Suppl_3), A14112-A14112, 2020 | 1 | 2020 |
| Apabetalone, an epigenetic BET inhibitor in a phase 3 trial, inhibits vascular inflammation and cellular adhesion leading to beneficial outcomes in CVD patients L Tsujikawa, L Fu, S Das, BD Rakai, CD Sarsons, C Halliday, SC Stotz, ... Journal of the American College of Cardiology 73 (9S1), 2063-2063, 2019 | 1 | 2019 |
| Relating Quantum Dot Association with Human Endothelial Cells with their Cytotoxic Effects KV Villar, H Lee, J Kennard, CD Sarsons, HI Labouta, D Cramb, ... Journal of Undergraduate Research in Alberta 5 (1), 2015 | 1 | 2015 |
| The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation S Wasiak, L Fu, E Daze, D Gilham, BD Rakai, SC Stotz, LM Tsujikawa, ... Translational Neuroscience 14 (1), 20220332, 2023 | | 2023 |
| Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells CD Sarsons, D Gilham, LM Tsujikawa, S Wasiak, L Fu, BD Rakai, ... Biomedicines 11 (10), 2683, 2023 | | 2023 |
David CrambRyerson UniversityVerified email at ryerson.ca
